Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects (Q45839832)

16 December 2017

title

Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects (English)

1 reference

16 December 2017

1 reference

F de Wolf

1

1 reference

16 December 2017

J M Lange

2

1 reference

16 December 2017

J Goudsmit

3

1 reference

16 December 2017

P Cload

4

1 reference

16 December 2017

J de Gans

5

1 reference

16 December 2017

P T Schellekens

6

1 reference

16 December 2017

R A Coutinho

7

1 reference

16 December 2017

A P Fiddian

8

1 reference

16 December 2017

J van der Noordaa

9

1 reference

16 December 2017

language of work or name

English

0 references

publication date

1 February 1988

1 reference

16 December 2017

published in

The Lancet

1 reference

16 December 2017

volume

1

1 reference

16 December 2017

issue

8582

1 reference

16 December 2017

page(s)

373-376

1 reference

16 December 2017

Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Intra-blood-brain barrier synthesis of human immunodeficiency virus antigen and antibody in humans and chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Significant changes in HIV antigen level in the serum of patients treated with azidothymidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2888%2991179-8

7 January 2021

10.1016/S0140-6736(88)91179-8

Identifiers

DOI

1 reference

16 December 2017

PubMed ID

2893187

1 reference

16 December 2017